Revolution Medicines公司周五表示，其近期获批的胰腺癌药物Rasonque在接受过既往治疗的患者中改善了总生存期，无论患者是否携带驱动肿瘤生长的RAS突变。
Revolution Medicines said on Friday its recently approved pancreatic cancer drug Rasonque improved overall survival in previously treated patients, regardless of whether they carried an RAS mutation that drives tumor growth.
以下是该公司在马德里举行的欧洲肿瘤内科学会大会上公布的数据的更多细节：探索性分析显示，与化疗相比，Rasonque使所有接受评估的RAS亚组患者的死亡风险降低：在携带RAS突变的患者中降低39%至68%，在未发现RAS突变的患者中降低57%。RAS突变驱动肿瘤生长，在超过90%的胰腺癌病例中存在。该分析基于一项晚期研究，该研究入组了500名接受过既往治疗的患者，其中248人接受Rasonque治疗，252人接受化疗。
Here are more details from data presented at the European Society for Medical Oncology Congress in Madrid:
这款每日一次的口服药于8月获得美国快速批准，用于治疗已接受过既往治疗或无法接受联合化疗的转移性胰腺癌患者。分析显示，与多种标准化疗方案相比，Rasonque改善了总生存期。在既往接受过治疗的患者中也观察到总生存期的改善，包括癌症在先前治疗后六个月内扩散的患者，以及因转移性疾病接受过一次既往治疗的患者。
Exploratory analyses showed Rasonque reduced the risk of death versus chemotherapy across all evaluated RAS subgroups by 39% to 68% in patients with RAS mutations and by 57% in those with no identified RAS mutation RAS mutations drive tumor growth and are found in more than 90% of pancreatic cancer cases The analysis was based on a late-stage study enrolling 500 previously treated patients, 248 of whom received Rasonque and 252 chemotherapy The once-daily pill won speedy US approval in August to treat metastatic pancreatic cancer in patients who had received prior treatment or could not receive combination chemotherapy Analyses showed Rasonque improved overall survival compared with several standard chemotherapy regimens Improvement in overall survival was also seen in previously treated patients, including those whose cancer spread within six months of earlier therapy and those who had received one prior treatment for metastatic disease